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Bone tissue engineering is a very challenging and promising field, which handles with the limitations of bone 
regenerative capacity and the failure of current orthopedic implants [1]. 
This work describes the preparation and characterization of an injectable dextrin-based hydrogel (oDex) able to 
incorporate nanoparticles, cells, biomolecules or ŁŬŪŤŨÙÛŤŸĚgranules [2]. Bonelike0 is a Biosckin-molecular and 
cell therapies S.A. proprietary synthetic bone graft, and the outcome of the project will result in a novel 
injectable presentation of this product. The hydrogel was produced by dextrin oxidation with sodium periodate 
followed by cross-linking with a dihydrazide [3]. In vitro characterization of oDex hydrogel has shown 
acceptable mechanical properties, overall good biocompatibility and the ability to be combined with other 
materials such as a nanogel and urinary bladder matrix, without affecting its structure. Subcutaneous implants 
were performed in Sasco Sprague Dawley rats and, after 3 and 15 days post-implantation, a quantitative 
evaluation according to ISO 10993 was performed, leading to a classification of the implanted material as slight 
irritant. The performance of oDex hydrogel combined with Bonelike granules and/or UBM in bone defects was 
investigated in New Zealand rabbits showing that oDex does not constitute a barrier for cellular colonization 
and proliferation. A sterilization protocol for oDex hydrogels by gamma and beta radiation was investigated 
through irradiation of oxidized dextrin solutions. Despite both kinds of radiation induced slight differences in 
the storage modulus of the hydrogels, indicating the occurrence of chain scission/cross-linking effects on the 
dextrin chain, all materials were gelable after the irradiation treatments. oDex hydrogels provides a system 
that can ca rry and stabilize cells, nanogels, Bonelike • granules and other biomolecules. It is a promising 
biomaterial due to its biocompatibility, and potential to promote an adequate environment for bone 
regeneration. 
This work has been developed in the scope of an European project that allowed collaborations with research 
groups, which have co mplementary expert ise. The tight collaboration between University of Min ho and Bioskin 
S.A. company, envisioning technology t ransfer and product valorization, has resulted in a published 
international patent of the product (W02011070529A2) (4]. Currently, a new set of pre-cl inical trials in sheep 
models are being planned as well as the submission of a request for the authorizat ion for the clinical trials. 
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